Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2010 Oct;123(3):781-3.
doi: 10.1007/s10549-010-1104-8. Epub 2010 Aug 6.

Predicting skeletal complications in metastatic breast cancer raises challenges

Catherine Van Poznak  1
Affiliations
Comment

Predicting skeletal complications in metastatic breast cancer raises challenges

Catherine Van Poznak. Breast Cancer Res Treat. 2010 Oct.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Global, regional estimates of cancer mortality, incidence by site: II. Results for the global burden of disease 2000. BMC Cancer. 2002;2:37. - PMC - PubMed
    1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165–176. - PubMed
    1. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588–1594. - PubMed
    1. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335(24):1785–1791. - PubMed
    1. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Glück S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999;17(3):846–854. - PubMed

MeSH terms